At the time the present study was conducted, ESMO expert consensus statements advised considering HER2-low breast cancer as a heterogeneous disease primarily influenced by hormone receptor expression rather than a distinct molecular entity27. This evidence concerns the gene ERBB2 and breast carcinoma.